Morgan Stanley Raises Philip Morris Price Target on Zyn and IQOS Growth Confidence

Morgan Stanley has revised its price target for Philip Morris International (PM) upward, citing strong growth potential for the company's nicotine pouch Zyn and heated tobacco product IQOS. Analysts expect these products to boost Philip Morris's revenue and profit margins. The new price target is set at a higher level compared to previous estimates. Morgan Stanley noted that Zyn's rapid adoption in the US market and IQOS's expansion in international markets are strengthening the company's growth narrative. In particular, Zyn has gained significant market share due to regulatory approvals and consumer demand. Philip Morris has been focusing on smoke-free products to offset declining traditional cigarette sales. The company reported strong performance for IQOS in Europe and Asia, with Zyn's success in the US supporting this strategy. Morgan Stanley believes these products will play a key role in achieving the company's long-term growth targets. While maintaining a positive outlook on Philip Morris's stock, analysts added that investors should consider factors such as regulatory risks and competitive pressures. The price target revision is seen as a reflection of confidence in the company's innovative product portfolio. This is not investment advice.